I hear you. However, time, the amount of money & the resultant price of the stock are important. It is better to be proactive & not wish you had been. It is not $1.35 that is involved, it is the present value of the company [3.50-4.00].
Because the concept of csc therapy is to extend PFS [or to OS] beyond primary treatment clinical timing is probably extended. The company should work either with a larger company [research & financial] or merge with a company such as Infinity. Infinity needs candidates but has money,
Basically the company is starting [research] anew. If they can prove their thoughts [FAK inhibitor] they have a saleable company at a much, much higher price. Time/cash is the bogey.
Vera stem appears to be the only one working on FAK inhibition. The interest in Stemcentrix is related to work onDLL 3 [notch]. OMED lead candidate is DLL 2 . They are not involved with FAK [even though Max Wicha is a strong advocate] or DLL 3. Surprisingly not involved in DLL 3 because they believe it has limited scope. Boston Bio emphasis is on STAT3.
The huge price paid for Stemcentrix certainly gives some validity. However, what works, when and with what is still open.
Believe the company will be sold when they prove efficacy. Meanwhile stock will sell at a discount. Low stock price reduces institutional interest & firms that owned & sold are unlikely to return. The only exception would be if a breakthrough in the general csc area is picked up by the general press. Fidelity [all industries] has done well in the hold until the company sells itself area. CSC therapy on a long term maintenance basis is not all that bad.
Amazing - This company is worth more [ A LOT MORE] dead than alive. Perhaps the directors & large stockholders should think this over.
It is 3+ months since --. Are you planning on selling/exchanging [stemcentrix,Bosto Bio,Omed] for cash plus a bit & letting others do the job or do you have a research plan B? Would you FINALLY consider research partnerships? Noticed that Joanna joined Idera. Options issued but no purchases on the open market yet.
Best to all for the New Year.
Obviously the staff reduction included people [pharmavigilance & such] working on the trial. Command was the major activity of the company. I don't expect to hear much from management until they finalize their plans. Hopefully to include a research partnership.
Don't know if the price reflects a loss of confidence or complete disappointment. Some companies, such as Infinity, have had many failures & still retain investor confidence. I don't know of any other $70 million biotech with over $100million & Verastems exposure. Prior to the offering my recommendation was that they add a research partner. This would have enabled a higher price - particularly if the partner participated in the offering. Instead they sold stock into the open market prior to the offering! Boston Biomedical & OncoMed are examples of csc that that made deals early. VSTM is still determined to go it alone. Near term it would be interesting to know the new owners of the stock & of course the results of the ovarian trial.
A private company, so far, that is focusing on CSC recently raised additional money. The list of backers of Stemcentrix & the capitalization are quite interesting.
The interesting session was Sunday 5/31. As Dr. Wicha has been involved in csc research for a long time his remarks were particularly interesting. Immunotherapies will need to be combined with csc therapies. His comments on the importance of FAK inhibitors position as a key mode. Not new , the addition of csc by some oncology drugs. A lot going on.
I wish all those fighting cancer success. Nothing is proved [immunotherapy] on solid tumors. I do know that custom treatments like this are fantasticality expensive. Perhaps the first csc drug to market will attract attention.
The price was certainly lower than expected. Many biotechs have been raising $ since the first of the year. No pre offering stockholder has a profit. The ones in shock are those who participated in the original offerings [$10 & $15] & saw 3 years of progress. However, this is part of the risk investing in any venture capital [no product, no cash flow] firm. The stock looks attractive here on a risk-reward & timing [operational] basis. Looking for positives: money in hand early, $ until 2017, insiders participated, company retained 100% of benefits.
The thing that received my attention was the number of leads,teasers, that have resulted from their ongoing work. The company went public exactly 3 years ago @ $10. I wonder what it would sell for if going public for the first time now. Certainly more than the present price. I do recall that the base for Genzyme was also an orphan drug.
The excellent work being done by research organizations continue to show the negative effects of CSC in oncology. However, substantial work will be necessary to provide aid to the patients.
If a director would recommend when next raising $ selling stock, at a premium, directly to a larger company & joining in a research collaboration.
The recent presentation in London was well done. If you can decipher the accent it is worth a listen.
The excellent work being done by research organizations reinforces the known negative effects of CSC in oncology. However, substantial work is necessary to provide aid to the patients.
If a director would recommend when next raising $ sell stock, at a premium, to a larger company & join in a research collaboration.
The recent presentation, in London, was well done. If you can decipher the accent it is worth a listen.
A long shot - mostly for knowledge. They admit it is a [high hurdle]. Give them credit they will tell it , good or bad, as it is.